Dimethyl Fumarate Capsule, Delayed Release
Product Images NDC 51407-441

6 FDA label images from Golden State Medical Supply, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Dimethyl Fumarate (NDC 51407-441). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407 441 60

51407 441 60
Label for dimethyl fumarate delayed-release capsules, 240 mg strength. The label shows the NDC 51407-441-60, contains 60 capsules, and is manufactured by TWi Pharmaceuticals, marketed by GSMS, Incorporated. Instructions include dosage, storage conditions, and safety warnings about light protection and keeping out of reach of children.*
FDA Label Image

51407 442 14

51407 442 14
Label for Dimethyl Fumarate delayed-release capsules, 120 mg strength, in a 14-capsule package. The label includes dosage instructions to take one capsule by mouth twice daily and swallowing the capsule whole. It also states storage guidelines, that the capsule contains color additives including FD&C Yellow No. 5, and includes manufacturer TWi Pharmaceuticals, Inc. and marketer GSMS, Incorporated branding with location in Camarillo, CA.*
FDA Label Image

Chemical Structure

Chemical Structure
Chemical structure diagram of dimethyl fumarate, showing atoms and bonds of the molecule.*
FDA Label Image

Image Description (Dtfclinical)

Image Description (Dtfclinical)
This line graph compares the percentage of subjects with confirmed progression of disability over time in weeks for placebo versus dimethyl fumarate delayed-release capsules 240 mg BID groups. The placebo group shows a higher percentage progressing to disability over 96 weeks compared to the dimethyl fumarate group, illustrating differences in disability progression rates between the two treatments.*
FDA Label Image

Logo 1

FDA Label Image

Logo2.jpg (Logo 2)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.